Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
about
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisTargeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaOutcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis modelLenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activityGold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy.Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer.Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation.Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.Monitoring of tumor vascular normalization: the key points from basic research to clinical application
P2860
Q26740812-159D071B-EA45-4A2F-9259-BB108F94CA2EQ26747666-E4641D77-ADDA-4B65-949F-874ABAA91E0CQ33441574-DB9B8D7A-58D9-4270-9C00-237F4577C0B8Q33787355-FCC33379-0463-4C73-9D69-12E55E4E47AFQ35777174-7DFFE2D4-04D1-4D98-BD18-6BA763852F71Q36871777-68F3C498-A20B-4479-A35F-9F809B6D243CQ37137190-CF1B7E1D-82EE-4975-9532-64AB50FCC5C0Q37143937-33EC212E-03FC-4062-85C7-F397AC4FF2BCQ38645097-2EA0D1AE-AC80-4B72-AA68-2C9EF29177F2Q38835312-0D2D01CC-B211-4368-B344-093B99CD506DQ39556310-B4DB3A78-4A59-44F6-AD83-DF820F784463Q40979902-FD51BF16-0354-43E1-B90E-ACA214FDB60BQ47114407-24A0BE1C-5E29-43B1-8D9A-582A3D7DF6F5Q57484416-3BE4CA2B-D3BC-485A-BF83-50E94A01298F
P2860
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Transient antiangiogenic treat ...... peutic outcome in lung cancer.
@en
Transient antiangiogenic treat ...... peutic outcome in lung cancer.
@nl
type
label
Transient antiangiogenic treat ...... peutic outcome in lung cancer.
@en
Transient antiangiogenic treat ...... peutic outcome in lung cancer.
@nl
prefLabel
Transient antiangiogenic treat ...... peutic outcome in lung cancer.
@en
Transient antiangiogenic treat ...... peutic outcome in lung cancer.
@nl
P2093
P50
P1433
P1476
Transient antiangiogenic treat ...... peutic outcome in lung cancer.
@en
P2093
Alexandra Florin
Caroline Wieczorek
Jakob Schöttle
Joanna Adamczak
Maike Siobal
Roland T Ullrich
Thomas Franz
Yvonne Hinze
P304
P356
10.1158/0008-5472.CAN-13-2986
P407
P577
2014-03-27T00:00:00Z